GlobeNewswire by notified

Dakar 2 Summit: Development partners to commit $30 billion to boost food production in Africa


DAKAR, Senegal, Jan. 30, 2023 (GLOBE NEWSWIRE) -- The second Africa food summit in Senegal ended on Friday, with development partners agreeing to commit $30 billion to back the continent’s resolve to boost agricultural productivity and become a breadbasket for the world.

Among the development partners are the African Development Bank which plans to contribute $10 billion over five years, and the Islamic Development Bank, which intends to provide $5 billion.

The Dakar 2 Summit—under the theme ‘Feed Africa: food sovereignty and resilience’—adopted a Declaration on the implementation of the Summit’s resolution, to be submitted to the African Union.

Organized by the Senegalese government and the African Development Bank, the Summit rallied dozens of dignitaries, including 34 heads of state and government, 70 government ministers, and development partners, to work tirelessly on compacts that would transform agriculture across Africa. The President of Ireland Michael D Higgins attended all the three days of the summit.

Addressing the closing plenary, African Development Bank Group President Dr Akinwumi Adesina said the continent and its partners are determined to see results and that implementation is critical to boosting food production and feeding Africa.

“The message was clear: we will work together to strongly support the implementation of the Food and Agriculture Delivery Compacts at country levels,” Adesina said.

He said the heads of state and government committed to setting up presidential high level advisory councils to oversee the implementation of the Compacts, to be chaired by the presidents themselves in their respective countries.

Strong commitment to deliver

“With strong collective determination and resolve, we will work in coordination and partnerships to help countries to deliver success,” he affirmed.

Adesina commended the high turnout at the event. “We came in response to a clarion call out of Africa that it is time for Africa to feed Africa. The clarion call was that the time is right, and the time is now for Africa to feed itself. We came from Africa. We came from around the world.”

He said that Dakar 2 Summit would be remembered as a key moment in Africa’s ability to feed itself and achieve food self-sufficiency and food sovereignty: “We leave with a determination and resolve to feed Africa. With hands together and in locked steps, we will reach our destination: An Africa that finally feeds itself. An Africa that develops with pride.” 

In the Dakar Declaration, the leaders agreed to allocate at least 10% of public expenditure to increase funding for agriculture. They also resolved to deploy robust production packages to boost productivity and increase resilience to achieve food security and self-sufficiency.

In his closing remarks, Senegalese Prime Minister Amadou Ba called the summit “a resounding success.”

“Agriculture creates jobs and promotes wealth and health,” he said and called on all citizens of Africa to come together and agree on a joint agenda steered by Africans for Africans.

Prime Minister Ba added: “It’s a paradox that Africa is the largest continent but also the most dependent. Starting now, we must do away with dependency. Africa should consume what it produces and produce what it consumes.”

Global support

Irish President Michael Higgins, who attended all three days of the summit, called for global support for the ‘Feed Africa’ agenda. 

“Let us make this century Africa’s Century, one which will see the continent become free from hunger, a shared continent in a global family, one based on the firm foundations of respect for each nation’s institutions, traditions, experiences, and wisdoms,” President Higgins said.

In a video message, Netherlands Director-General for International Cooperation Kitty Van Den Heijden announced that her country would commit an additional €450 million over the next five years to food security programs with a focus on Sub-Saharan Africa. She said the country would also support the African Emergency Food Production Facility of the African Development Bank with $30 million.

“We don’t have time to waste; we need to take action and build more resilient food systems,” she added.

The president of the Islamic Development Bank, Dr. Muhammad Al Jasser, delivered a statement pledging continued support to boost food production in Africa. Canada and Germany also made commitments to support the Feed Africa agenda.

Click here to read President Adesina’s full speech

Click here to read Dakar Declaration

Click here for photos from the summit

Contact: Kwasi Kpodo |

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer30.5.2024 09:00:00 CEST | Press release

PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that earlier this month patients in France received the first doses of PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Today’s news follows earlier announcements by Curium of the first doses for Greece in November 2023, and for 2024 first doses for Italy in February, for the Netherlands in March, and for Germany in May. Benoit Woessmer, PET Europe CEO at Curium commented, “We are extremely pleased

Interim financial report for 1 January - 31 March 2024 for FirstFarms A/S30.5.2024 09:00:00 CEST | Press release

Satisfactory start of 2024 FirstFarms has had a satisfactory start to the year. A number of significant events will have a positive impact on the Group going forward. FirstFarms has in the accounting period Q1-2024 realised: · A turnover of 104 mDKK (2023: 109 mDKK) · An EBITDA of 36 mDKK (2023: 33 mDKK) · An EBIT of 22 mDKK (2023: 22 mDKK) · A pre-tax result of 14 mDKK (2023: 20 mDKK) EBITDA has improved by 3.0 mDKK compared to the same period last year. The decrease in turnover is due to lower sale of previous years’ crops compared to Q1 2023. The lower pre-tax result compared to the same period last year is primarily due to a higher interest rate level, but also completed investments in 2023. CEO of FirstFarms, Anders H. Nørgaard, is satisfied with the Q1 results: "Our animal production has got off to a good start, and we have increased the turnover of pigs and milk by a total of 9 mDKK compared to the same period last year. "The low crop prices have continued into 2024. This means

Delårsrapport for 1. januar - 31. marts 2024 for FirstFarms A/S30.5.2024 09:00:00 CEST | pressemeddelelse

Tilfredsstillende start på 2024 FirstFarms har fået en tilfredsstillende start på året. En række væsentlige begivenheder får positiv betydning for koncernen fremadrettet. FirstFarms har i regnskabsperioden Q1-2024 realiseret: · En omsætning på 104 mDKK (2023: 109 mDKK) · Et EBITDA på 36 mDKK (2023: 33 mDKK) · Et EBIT på 22 mDKK (2023: 22 mDKK) · Et resultat før skat på 14 mDKK (2023: 20 mDKK) EBITDA er forbedret med 3,0 mDKK sammenlignet med samme periode sidste år. Faldet i omsætning skyldes lavere salg af tidligere års afgrøder i forhold til Q1 2023. Det lavere resultat før skat i forhold til samme periode sidste år, skyldes primært et højere renteniveau men også gennemførte investeringer i 2023 Administrerende direktør i FirstFarms, Anders H. Nørgaard, er tilfreds med Q1-resultatet: ”Vores animalske produktion er kommet godt fra start, og vi har løftet omsætningen på grise og mælk med samlet 9 mDKK i forhold til samme periode sidste år. ”De lave afgrødepriser er fortsat ind i 2024.

Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 202430.5.2024 08:30:30 CEST | Press release

Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May 30, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced that a post-hoc analysis of the Phase 3 clinical study results for EPYSQLI™ (SB12), a biosimilar to Soliris1 (eculizumab), will be presented at the 29th European Hematology Association 2024 (EHA2024) Hybrid Congress held in Madrid, Spain and virtually, from June 13 to 16, 2024. SB12 has shown equivalent efficacy with reference eculizumab (ECU) by lactate dehydrogenase (LDH) and comparable safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles in paroxysmal nocturnal hemoglobinuria (PNH) through the pivotal Phase 3 study.2 The post-hoc analysis of SB12 pivotal Phase 3 study presented at EHA2024 compared the proportion of patients remaining transfusion-free (“transfusion avoidance”) among those treated with SB12 or ECU, respectively. Eculizumab is kn

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents30.5.2024 08:30:00 CEST | Press release

Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of June 20, 2024. Shareholders are invited to participate in the Combined General Meeting that will be held on June 20, 2024 at 9 a.m. at Hôtel Castel Burgond, 3 route de Troyes, 21121 Daix (France). The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) n°58 of May 13, 2024 and a translation was filed with the

HiddenA line styled icon from Orion Icon Library.Eye